Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 15, 2025

Europe Gauges Fallout From Trump’s Year of Trade Chaos

View original at finance.yahoo.com
Europe Gauges Fallout From Trump’s Year of Trade Chaos Bound aluminum plates ahead of shipping at an aluminium smelter near Dunkirk, France…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Still-elevated uncertainty, higher effective tariffs, a stronger euro and increased global competition are expected to hold back growth

    80% confidence
  • The European Commission is likely to raise the 2025 GDP estimate this time around

    80% confidence
  • Uncertainty is shaving about 0.5 percentage point off France's expansion, with domestic political and budget turbulence accounting for at least 0.2 point of that

    80% confidence
  • The economy may experience another period of soft business investment and weak external demand as a result of elevated uncertainty and fewer purchases from the other side of the Atlantic

    80% confidence
  • The European Central Bank anticipated 1% growth for 2026 in its September forecasting round

    80% confidence
  • Bank Indonesia Governor Perry Warjiyo likely to signal room for further cuts in the coming year

    80% confidence
  • The European Commission earlier predicted a 0.9% increase for gross domestic product in the euro area for 2025

    80% confidence
  • We forecast euro-area GDP growth to remain below trend in the final quarter of 2025 at 0.1%

    80% confidence
  • Rodriguez Ceja sees a quarter-point cut to 7% next month as highly likely

    80% confidence
  • Germany's Council of Economic Experts has lowered its outlook for expansion in 2026 to below 1%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com